Valneva SE (VALN) Cash from Investing Activities (2021 - 2026)
Valneva SE's (VALN) quarterly Cash from Investing Activities came in at $321955.1 in Q1 2026, up 131.85% year-on-year from $138863.8 in Q1 2025, and up 204.77% quarter-over-quarter from -$307307.5 in Q4 2025.
Valneva SE (VALN) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Valneva SE has disclosed Cash from Investing Activities across 6 years of filings, most recently posting $321955.1 for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at $321955.1, up 131.85% year-over-year; the trailing twelve-month figure through Mar 2026 was -$525913.1 (up 95.59% YoY), and the FY2025 annual result was -$2.0 million, down 102.42% from the prior year.
- Cash from Investing Activities came in at $321955.1 for Q1 2026 at Valneva SE, up from -$307307.5 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $7.2 billion in Q3 2023 to a low of -$7.2 billion in Q2 2023.
- The 5-year median for Cash from Investing Activities is -$1.0 million (2025), against an average of $1.6 million.
- Peak annual rise in Cash from Investing Activities reached 110357.31% in 2023, while the deepest fall reached 103203.17% in 2023.
- Valneva SE's Cash from Investing Activities stood at -$6.7 million in 2022, then slumped by 161.86% to -$17.6 million in 2023, then soared by 128.54% to $5.0 million in 2024, then plunged by 106.13% to -$307307.5 in 2025, then jumped by 204.77% to $321955.1 in 2026.
- The last three Cash from Investing Activities figures came in at $321955.1 (Q1 2026), -$307307.5 (Q4 2025), and $230303.9 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 579,519.10 |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 321,955.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 321,955.05 |
| Mar 31, 2026 | 321,955.05 |
| Dec 31, 2025 | -307,307.49 |
| Dec 31, 2025 | -307,307.49 |
| Sep 30, 2025 | 230,303.85 |
| Sep 30, 2025 | 230,303.85 |
| Jun 30, 2025 | -770,864.55 |
| Jun 30, 2025 | -770,864.55 |
| Mar 31, 2025 | -1.01 Mn |
| Mar 31, 2025 | -1.01 Mn |
| Dec 31, 2024 | 5.01 Mn |
| Dec 31, 2024 | 5.01 Mn |
| Sep 30, 2024 | -16.89 Mn |
| Sep 30, 2024 | -16.89 Mn |
| Jun 30, 2024 | 963,814.38 |
| Jun 30, 2024 | 963,814.38 |
| Mar 31, 2024 | 94.20 Mn |
| Mar 31, 2024 | 94.20 Mn |
| Dec 31, 2023 | -17.56 Mn |
| Dec 31, 2023 | -17.56 Mn |